These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 32893736)

  • 1. The role of pharmacogenomics in the personalization of Parkinson's disease treatment.
    Redenšek S; Dolžan V
    Pharmacogenomics; 2020 Sep; 21(14):1033-1043. PubMed ID: 32893736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetic considerations in the treatment of Parkinson's disease.
    Kurzawski M; Białecka M; Droździk M
    Neurodegener Dis Manag; 2015; 5(1):27-35. PubMed ID: 25711452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's disease pharmacogenomics: new findings and perspectives.
    Schumacher-Schuh AF; Rieder CR; Hutz MH
    Pharmacogenomics; 2014 Jun; 15(9):1253-71. PubMed ID: 25141900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenomics-a New Frontier for Individualized Treatment of Parkinson's Disease.
    Liu JS; Chen Y; Shi DD; Zhang BR; Pu JL
    Curr Neuropharmacol; 2023; 21(3):536-546. PubMed ID: 36582064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study.
    Masellis M; Collinson S; Freeman N; Tampakeras M; Levy J; Tchelet A; Eyal E; Berkovich E; Eliaz RE; Abler V; Grossman I; Fitzer-Attas C; Tiwari A; Hayden MR; Kennedy JL; Lang AE; Knight J;
    Brain; 2016 Jul; 139(Pt 7):2050-62. PubMed ID: 27190009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and Clinical-Pharmacogenetic Models for Prediction of the Most Common Psychiatric Complications Due to Dopaminergic Treatment in Parkinson's Disease.
    Redenšek S; Jenko Bizjan B; Trošt M; Dolžan V
    Int J Neuropsychopharmacol; 2020 Nov; 23(8):496-504. PubMed ID: 32710539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetics and Treatment Response in Parkinson's Disease: An Update on Pharmacogenetic Studies.
    Politi C; Ciccacci C; Novelli G; Borgiani P
    Neuromolecular Med; 2018 Mar; 20(1):1-17. PubMed ID: 29305687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics of drug response in Parkinson's disease.
    Džoljić E; Novaković I; Krajinovic M; Grbatinić I; Kostić V
    Int J Neurosci; 2015; 125(9):635-44. PubMed ID: 25226559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Parkinson's disease drugs and pharmacogenetic considerations.
    Agúndez JA; García-Martín E; Alonso-Navarro H; Jiménez-Jiménez FJ
    Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):859-74. PubMed ID: 23565891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emerging science of precision medicine and pharmacogenomics for Parkinson's disease.
    Payami H
    Mov Disord; 2017 Aug; 32(8):1139-1146. PubMed ID: 28686320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How close are we to individualized medicine for Parkinson's disease?
    Kim HJ; Jeon B
    Expert Rev Neurother; 2016 Jul; 16(7):815-30. PubMed ID: 27105072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics of antiparkinsonian drug treatment: a systematic review.
    Arbouw ME; van Vugt JP; Egberts TC; Guchelaar HJ
    Pharmacogenomics; 2007 Feb; 8(2):159-76. PubMed ID: 17286539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translating genotype data of 44,000 biobank participants into clinical pharmacogenetic recommendations: challenges and solutions.
    Reisberg S; Krebs K; Lepamets M; Kals M; Mägi R; Metsalu K; Lauschke VM; Vilo J; Milani L
    Genet Med; 2019 Jun; 21(6):1345-1354. PubMed ID: 30327539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translational Informatics for Parkinson's Disease: from Big Biomedical Data to Small Actionable Alterations.
    Shen B; Lin Y; Bi C; Zhou S; Bai Z; Zheng G; Zhou J
    Genomics Proteomics Bioinformatics; 2019 Aug; 17(4):415-429. PubMed ID: 31786313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From Genomics to Omics Landscapes of Parkinson's Disease: Revealing the Molecular Mechanisms.
    Redenšek S; Dolžan V; Kunej T
    OMICS; 2018 Jan; 22(1):1-16. PubMed ID: 29356624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomics and Personalized Medicine.
    Cecchin E; Stocco G
    Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32580376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenomics of Alzheimer's and Parkinson's diseases.
    Cacabelos R
    Neurosci Lett; 2020 May; 726():133807. PubMed ID: 30236877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized medicine in Parkinson's disease: Time to be precise.
    Titova N; Chaudhuri KR
    Mov Disord; 2017 Aug; 32(8):1147-1154. PubMed ID: 28605054
    [No Abstract]   [Full Text] [Related]  

  • 19. Advances in understanding genomic markers and pharmacogenetics of Parkinson's disease.
    Jiménez-Jiménez FJ; Alonso-Navarro H; García-Martín E; Agúndez JA
    Expert Opin Drug Metab Toxicol; 2016; 12(4):433-48. PubMed ID: 26910127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalized Medicine and Nonmotor Symptoms in Parkinson's Disease.
    Titova N; Chaudhuri KR
    Int Rev Neurobiol; 2017; 134():1257-1281. PubMed ID: 28805572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.